Veronica Craine
YOU?
Author Swipe
View article: 127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial
127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial Open
IMpassion050 (NCT03726879) showed no increase in pathological complete response (pCR; ypT0/is ypN0) rates for neoadjuvant A + PH + CT vs. placebo (pbo) + PH + CT in the intention-to-treat (ITT) or PD-L1+ populations in patients (pts) with …
View article: 114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study Open
The primary analysis of the FeDeriCa study (NCT03493854; Tan AR, et al. Lancet Oncol 2021) showed that PH FDC SC cycle 7 P and H serum trough concentrations were non-inferior to intravenous (IV) P and H, with comparable total pathological …
View article: Patient‐ versus clinician‐reported symptoms in the POLARIX study
Patient‐ versus clinician‐reported symptoms in the POLARIX study Open
Introduction: The safety profiles of novel agents are mainly based on clinician-reported adverse events (AEs) from clinical trials. Patient-reported outcomes (PROs) may better represent the treatment burden experienced by patients (pts) co…
View article: Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study Open
Introduction: In the Phase 3 POLARIX study (NCT03274492), polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab, cyclop…
View article: Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma Open
Introduction: The best treatment for young patients with high-risk diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Results of the phase 3 R-MegaCHOEP study showed promising results using etoposide in combination with R-C…
View article: Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma Open
ClinicalTrials.gov Identifier: NCT02420821.